AstraZeneca PLC — Regulatory Filings 2019

May 1, 2019

6-K 1 a7562x.htm DIRECTOR/PDMR SHAREHOLDING Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2019 Issuer Direct Corporation Blueprint

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of May 2019

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Director/PDMR Shareholding

1 May 2019 12:00 BST

Transactions by Persons Discharging Managerial Responsibilities

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 29 and 30 April 2019, it was notified of transactions in the Company's ordinary shares of $0.25 each (Ordinary Shares) and American Depositary Shares (ADSs) by certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) as set out below. Two ADSs are equivalent to one Ordinary Share.

PDMR	Position	Nature of the transaction	Quantity	Price
Pascal
Soriot	Chief
Executive Officer	Purchase
of Ordinary Shares	17,100	GB£58.255
Philip
Broadley	Non-Executive
Director	Purchase
of Ordinary Shares	520	GB£57.38
Sheri
McCoy	Non-Executive
Director	Purchase
of ADSs	2,372	US$38.1783
Sheri
McCoy	Non-Executive
Director	Purchase
of ADSs	100	US$38.172
Deborah
DiSanzo	Non-Executive
Director	Purchase
of ADSs	1,000	US$38.3056

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

| 1 — a) | Details of the person discharging managerial responsibilities /
person closely associated — Name | Pascal
Soriot | |
| --- | --- | --- | --- |
| 2 | Reason for the notification | | |
| a) | Position/status | Chief
Executive Officer | |
| b) | Initial notification /Amendment | Initial
notification | |
| 3 | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | AstraZeneca
PLC | |
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description of the financial instrument, type of
instrument Identification
code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 | |
| b) | Nature of the transaction | Share
purchase | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | GB£58.255 | 17,100 |
| d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction | |
| e) | Date of the transaction | 29
April 2019 | |
| f) | Place of the transaction | XLON | |

| 1 — a) | Details of the person discharging managerial responsibilities /
person closely associated — Name | Philip
Broadley | |
| --- | --- | --- | --- |
| 2 | Reason for the notification | | |
| a) | Position/status | Non-Executive
Director | |
| b) | Initial notification /Amendment | Initial
notification | |
| 3 | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | AstraZeneca
PLC | |
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description of the financial instrument, type of
instrument Identification
code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 | |
| b) | Nature of the transaction | Share
purchase | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | GB£57.38 | 520 |
| d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction | |
| e) | Date of the transaction | 30
April 2019 | |
| f) | Place of the transaction | XLON | |

| 1 — a) | Details of the person discharging managerial responsibilities /
person closely associated — Name | Sheri
McCoy | |
| --- | --- | --- | --- |
| 2 | Reason for the notification | | |
| a) | Position/status | Non-Executive
Director | |
| b) | Initial notification /Amendment | Initial
notification | |
| 3 | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | AstraZeneca
PLC | |
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description of the financial instrument, type of
instrument Identification
code | AstraZeneca PLC American Depositary Shares CUSIP: 046353108 | |
| b) | Nature of the transaction | Purchase
of AstraZeneca PLC American Depositary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | US$38.1783 | 2,372 |
| | | US$38.175 | 100 |
| d) | Aggregated information - Aggregated volume - Price | 2,472 US$38.178 | |
| e) | Date of the transaction | 29
April 2019 | |
| f) | Place of the transaction | NYSE | |

| 1 — a) | Details of the person discharging managerial responsibilities /
person closely associated — Name | Deborah
DiSanzo | |
| --- | --- | --- | --- |
| 2 | Reason for the notification | | |
| a) | Position/status | Non-Executive
Director | |
| b) | Initial notification /Amendment | Initial
notification | |
| 3 | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | AstraZeneca
PLC | |
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description of the financial instrument, type of
instrument Identification
code | AstraZeneca PLC American Depositary Shares CUSIP: 046353108 | |
| b) | Nature of the transaction | Purchase
of AstraZeneca PLC American Depositary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | US$38.3056 | 1,000 |
| d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction | |
| e) | Date of the transaction | 29
April 2019 | |
| f) | Place of the transaction | NYSE | |

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @ AstraZeneca .

| Media
Relations — Gonzalo
Viña | UK/Global | +44 203
749 5916 |
| --- | --- | --- |
| Rob
Skelding | UK/Global | +44 203
749 5821 |
| Matt
Kent | UK/Global | +44 203
749 5906 |
| Jennifer
Hursit | UK/Global | +44
203 749 5762 |
| Christina M
Hägerstrand | Sweden | +46 8 552 53 106 |
| Michele
Meixell | US | +1 302
885 2677 |
| Investor
Relations | | |
| Thomas
Kudsk Larsen | | +44 203
749 5712 |
| Henry
Wheeler | Oncology | +44 203
749 5797 |
| Christer
Gruvris | BioPharma
- Cardiovascular; Metabolism | +44 203
749 5711 |
| Nick
Stone | BioPharma
- Respiratory; Renal | +44 203
749 5716 |
| Josie
Afolabi | Other | +44 203
749 5631 |
| Craig
Marks | Finance;
Fixed Income | +44
7881 615 764 |
| Jennifer
Kretzmann | Retail
Investors; Corporate Access | +44 203
749 5824 |
| US
toll-free | | +1 866
381 72 77 |

Adrian Kemp

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 May 2019

| By: /s/
Adrian Kemp |
| --- |
| Name:
Adrian Kemp |
| Title:
Company Secretary |

page break